Inotiv stock is trading -73.5% below its average target price of $26 after marking a 23.3% during today's None session. Analysts are giving the small-cap Diagnostics & Research company an average rating of buy and target prices ranging from $4 to $64 per share.
The stock has an above average percentage of its shares sold short at 14.4%, and a short ratio of 1.48. 25.21% of the corporation's outstanding shares are owned by its managers and directors, indicating a strong degree of alignment between their interests and those of other shareholders. Finally, we also note that only a small number of institutional investors are invested in the stock, with 47.8% of Inotiv's shares being owned by this investor type.
Institutions Invested in Inotiv
| Holder | Shares | Date Reported | Percentage | Value |
|---|---|---|---|---|
| Wasatch Advisors Inc | 1,399,365 | 2022-09-29 | 5% | $9,641,624 |
| Blackrock Inc. | 1,033,666 | 2022-09-29 | 4% | $7,121,958 |
| Vanguard Group, Inc. (The) | 907,455 | 2022-09-29 | 4% | $6,252,364 |
| P2 Capital Partners, LLC | 715,705 | 2022-09-29 | 3% | $4,931,207 |
| Janus Henderson Group PLC | 567,535 | 2022-09-29 | 2% | $3,910,316 |
| Point72 Asset Management, L.P. | 518,937 | 2022-09-29 | 2% | $3,575,475 |
| Thrivent Financial For Lutherans | 513,286 | 2022-09-29 | 2% | $3,536,540 |
| Ophir Asset Management Pty Ltd | 435,190 | 2022-09-29 | 2% | $2,998,459 |
| Venator Capital Management Ltd. | 410,000 | 2022-09-29 | 2% | $2,824,899 |
| Renaissance Technologies, LLC | 377,565 | 2022-09-29 | 1% | $2,601,422 |
Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Inotiv.
